Hims & Hers Investors Have Until November 2 To Lead Lawsuit
News related to:Hims & Hers Health, Inc · 2 min read
SAN DIEGO, Sept. 15, 2026 /CourierPR/ -- Robbins Geller Rudman & Dowd LLP has announced that investors who purchased or acquired Hims & Hers Health, Inc. (NYSE: HIMS) securities between August 4, 2025, and July 29, 2026, inclusive, have until November 2, 2026, to seek appointment as lead plaintiff in a class action lawsuit. The lawsuit, captioned Velanki v. Hims & Hers Health, Inc., No. 26-cv-09313 (N.D. Cal.), alleges that the company and certain of its top executives violated the Securities Exchange Act of 1934.
According to the complaint, Hims & Hers Health, Inc. operates as a health and wellness platform that connects consumers to licensed healthcare professionals. The lawsuit claims that throughout the class period, the company made false and/or misleading statements and failed to disclose several key issues. Specifically, the lawsuit alleges that Hims & Hers shared consumers' health information with third-party advertising platforms, charged consumers for prescriptions almost immediately after they submitted an intake form, despite claiming they would consult with a medical provider to find a treatment that is "right for them." Additionally, the lawsuit asserts that these practices subjected the company to regulatory scrutiny, making it reasonably likely that Hims & Hers would incur fees and penalties.
On July 29, 2026, the Federal Trade Commission (FTC) announced it had filed a lawsuit against Hims & Hers, alleging that the company shared consumers' sensitive health information with third-party advertising platforms, despite claiming to maintain consumers' privacy. The FTC's complaint also states that Hims & Hers engages in deceptive advertising practices, including failing to clearly disclose that it charges consumers for prescriptions almost immediately after they submit an intake form. The news caused the price of Hims & Hers shares to decline nearly 15%.
The complaint further alleges that the FTC's lawsuit includes specific instances where Hims & Hers shared consumers' sensitive health information with third-party advertising companies and platforms, such as Meta Platforms, Inc. and Snap Inc. The lawsuit claims that these practices violated consumer protection laws and misled investors.
The Private Securities Litigation Reform Act of 1995 permits any investor who purchased or acquired Hims & Hers securities during the class period to seek appointment as lead plaintiff in the lawsuit. The lead plaintiff acts on behalf of all other class members in directing the lawsuit and can select a law firm of their choice to litigate the case. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.
Robbins Geller Rudman & Dowd LLP, one of the world's leading law firms representing investors in securities fraud and shareholder rights litigation, is handling the case. The firm has a history of significant recoveries for investors, including the largest ever recovery of $7.2 billion in In re Enron Corp. Sec. Litig.